TOMDF — Todos Medical Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.00m
- $36.78m
- $12.23m
Brief: Todos Medical Clia/Cap Lab Provista Submits Emergency Use Authorization Application For Monkeypox Pcr Test To Us FDA
Brief: Todos Medical Provides Corporate Update
Brief: Todos Medical Enters Into $50 Mln Contract To Supply Tollovid, CBD Products To Retail Distributor Company Nerd Hemp
Brief: Todos Medical Establishes Botanical Supplement Manufacturing Capabilities
Brief: Todos Medical Says It Is Able To Test For Both COVID-19 And Monkeypox From Same Saliva Sample
Brief: Todos Medical Announces Saliva-Only Monkeypox Testing At CLIA/CAP Clinical Lab Provista Diagnostics
Brief: Todos Medical Enrolls Female Long Covid Patient Unable To Secure Testing While Symptomatic For Monkeypox Into Provista Diagnostics Case Study Series
Brief: Todos Medical Initiates Monkeypox Diagnostic Case Studies After Being Approached By 4 Patients, Including 3 Women
Brief: Todos Medical Announces Commercialization Of Lesion And Saliva-Based Monkeypox PCR Testing
Brief: Todos Medical Completes Trial Design For Tollovid Long Covid Clinical Study In Adults
Brief: Todos Medical Announces First Two Contracts For PCR-Based Monkeypox Testing At CLIA/CAP Clinical Testing Laboratory Provista Diagnostics
Brief: Todos Medical Announces Positive Biomarker Data From Phase 2 Trial Of Tollovir In Hospitalized COVID Patients
Brief: Todos Medical Releases Preliminary Data From Market Research Study Of Acute And Long COVID Treatment
Brief: Todos Medical And NLC Pharma Announce Interim Data For Nlc-V-01 Phase 2 Clinical Trial
Brief: Todos Medical Announces Data Lock In Tollovir Phase 2 Clinical Trial
Has Engaged An Underwriter To Support Uplisting To Nasdaq In First Half Of 2022
Brief: Todos Medical Announces 2 New COVID-19 PCR Testing Reference Lab Agreements For CLIA/CAP Lab Provista Diagnostics
Brief: Todos Says All 31 Patients In COVID-19 Treatment Trial Have Completed Study Participation
Brief: Todos Medical Enters Into Binding Agreement To Acquire All 3Cl Protease Biology-Related Assets And Intellectual Property From NLC Pharma